Skip to main content

Advertisement

SpringerLink
Log in

Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

The aim of this trial was to examine the effects after 2 years of a single intravesical botulinum toxin-A injection (BTX-A). This prospective, observational study was conducted using urodynamic measurements and quality of life (QoL) assessment to document the effect after 2 years of a single 100 I.U. injection of BTX-A into the vesical detrusor muscle. Twenty-six patients were followed up for 2 years after a first intravesical BTX-A injection. Of these 26 patients, one was a primary failure, three were lost to follow-up, and 11 patients had a repeated injection at 5–26 months (one patient had a third injection). Seven of the remaining 11 patients in the single injection group were recommended repeated injection or another treatment, and four required no other treatment. In conclusion, 2 years after a single BTX-A injection statistically significant differences in urodynamics and an improvement in QoL could still be demonstrated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61:37–49

    Article  PubMed  Google Scholar 

  2. Herbison P, Hay-Smith J, Ellis G, Moore K (2003) Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 326:841–844

    Article  PubMed  CAS  Google Scholar 

  3. Chapple CR, Rechberger T, Al-Shukri S et al (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93:303–310

    Article  PubMed  CAS  Google Scholar 

  4. Hay-Smith J, Herbison P, Ellis G, Moore K (2002) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev:CD003781

  5. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K (2006) Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 332:455–459

    Article  PubMed  Google Scholar 

  6. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697

    Article  PubMed  CAS  Google Scholar 

  7. Werner M, Schmid DM, Schussler B (2005) Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 192:1735–1740

    Article  PubMed  CAS  Google Scholar 

  8. Schmid DM, Sauermann P, Werner M et al (2006) Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176:177–185

    Article  PubMed  CAS  Google Scholar 

  9. Rapp DE, Lucioni A, Katz EE, O'Connor RC, Gerber GS, Bales GT (2004) Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 63:1071–1075

    Article  PubMed  Google Scholar 

  10. Sahai A, Khan MS, Fowler C, Dasgupta P (2005) Botulinum toxin: a new dimension in the treatment of lower urinary tract dysfunction. Urology 65:211

    Article  PubMed  Google Scholar 

  11. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P (2005) A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174:984–989

    Article  PubMed  CAS  Google Scholar 

  12. Reitz A, Stohrer M, Kramer G et al (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510–515

    Article  PubMed  CAS  Google Scholar 

  13. Rajkumar GN, Small DR, Mustafa AW, Conn G (2005) A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 96:848–852

    Article  PubMed  CAS  Google Scholar 

  14. de Miguel F, Chancellor MB (2006) Pittsburgh experience with botulinum toxin A injection. Actas Urol Esp 30:310–314

    Article  PubMed  Google Scholar 

  15. Riccabona M, Koen M, Schindler M et al (2004) Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 171:845–848 discussion 848

    Article  PubMed  CAS  Google Scholar 

  16. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 104:1374–1379

    PubMed  CAS  Google Scholar 

  17. Rapp DE, Turk KW, Bales GT, Cook SP (2006) Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 175:1138–1142

    Article  PubMed  CAS  Google Scholar 

  18. Cui M, Khanijou S, Rubino J, Aoki KR (2004) Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107:125–133

    Article  PubMed  CAS  Google Scholar 

  19. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB (2004) Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 172:1529–1532

    Article  PubMed  CAS  Google Scholar 

  20. MacKenzie I, Burnstock G, Dolly JO (1982) The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 7:997–1006

    Article  PubMed  CAS  Google Scholar 

  21. Apostolidis A, Popat R, Yiangou Y et al (2005) Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174:977–982 discussion 982–983

    Article  PubMed  CAS  Google Scholar 

  22. Cockayne DA, Hamilton SG, Zhu QM et al (2000) Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 407:1011–1015

    Article  PubMed  CAS  Google Scholar 

  23. Khera M, Somogyi GT, Salas NA, Kiss S, Boone TB, Smith CP (2005) In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord-injured rats. Urology 66:208–212

    Article  PubMed  Google Scholar 

  24. Apostolidis A, Dasgupta P, Fowler CJ (2006) Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49:644–650

    Article  PubMed  CAS  Google Scholar 

  25. Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P (2006) Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49:528–535

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Cantonal Hospital Lucerne, Lucerne, Switzerland

    Stefanie Kuschel, Elke Faust & Bernhard Schuessler

  2. Department of Obstetrics and Gynecology, University Hospital Zurich, Zurich, Switzerland

    Matthias Werner

  3. Department of Urology, University Hospital Zurich, Zurich, Switzerland

    Daniel Max Schmid

Authors
  1. Stefanie Kuschel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthias Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Max Schmid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elke Faust
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bernhard Schuessler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefanie Kuschel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kuschel, S., Werner, M., Schmid, D.M. et al. Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up. Int Urogynecol J 19, 905–909 (2008). https://doi.org/10.1007/s00192-007-0548-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-007-0548-9

Keywords

Search

Navigation